Premium
A Biocompatible Free Radical Nanogenerator with Real‐Time Monitoring Capability for High Performance Sequential Hypoxic Tumor Therapy
Author(s) -
Wan Yingpeng,
Lu Guihong,
Zhang Jinfeng,
Wang Ziying,
Li Xiaozhen,
Chen Rui,
Cui Xiao,
Huang Zhongming,
Xiao Yafang,
Chelora Jipsa,
Zhang Wenjun,
Liu Yanhong,
Li Min,
Xie HaiYan,
Lee ChunSing
Publication year - 2019
Publication title -
advanced functional materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.069
H-Index - 322
eISSN - 1616-3028
pISSN - 1616-301X
DOI - 10.1002/adfm.201903436
Subject(s) - indocyanine green , photothermal therapy , tumor hypoxia , materials science , radical , bovine serum albumin , in vivo , photodynamic therapy , biocompatible material , tumor microenvironment , cancer cell , biophysics , nanotechnology , cancer research , biomedical engineering , cancer , radiation therapy , chemistry , tumor cells , medicine , biochemistry , biology , pathology , organic chemistry , surgery , microbiology and biotechnology
Hypoxic microenvironment severely reduces therapeutic efficacy of oxygen‐dependent photodynamic therapy in solid tumor due to the hampered cytotoxic oxygen radicals generation. Herein, a biocompatible nanoparticle (NP) is developed by combining bovine serum albumin, indocyanine green (ICG), and an oxygen‐independent radicals generator (AIPH) for efficient sequential cancer therapy, denoted as BIA NPs. Upon near‐infrared irradiation, the photothermal effect generated by ICG will induce rapid decomposition of AIPH to release cytotoxic alkyl radicals, leading to cancer cell death in both normoxic and hypoxic environments. Moreover, such nanosystem provides the highest AIPH loading capacity (14.9%) among all previously reported radical nanogenerators (generally from 5–8%). Additionally, the aggregation‐quenched fluorescence of ICG molecules in the NPs can be gradually released and recovered upon irradiation enabling real‐time drug release monitoring. More attractively, these BIA NPs exhibit remarkable anticancer effects both in vitro and in vivo, achieving 100% tumor elimination and 100% survival rate among 50 days treatment. These results highlight that this albumin‐based nanoplatform is promising for high‐performance cancer therapy circumventing hypoxic tumor environment and possessing great potential for future clinical translation.